BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook

Published 04/08/2025, 11:56
© Reuters.

MAINZ, Germany - On Monday, BioNTech SE (NASDAQ:BNTX) reported second quarter 2025 revenue that doubled YoY to €260.8 million, significantly exceeding analyst estimates of €137.9 million.

The company’s shares rose 2.45% in pre-market trading after the quarterly release.

The biotechnology firm posted a net loss of €386.6 million or -€1.60 per share, slightly worse than the expected -€1.41 per share.

The revenue beat comes as BioNTech continues its strategic pivot from COVID-19 vaccines toward oncology, highlighted by a transformative collaboration with Bristol Myers (NYSE:BMY) Squibb for its bispecific antibody candidate BNT327. The deal, which includes a $1.5 billion upfront payment expected in the third quarter, plus $2 billion in non-contingent payments through 2028 and up to $7.6 billion in potential milestone payments, significantly strengthens BioNTech’s financial position.

"In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by strengthening the two pillars of our oncology strategy," said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech.

Despite the strong revenue performance, the company reaffirmed its full-year 2025 revenue guidance of €1.7-2.2 billion, below the consensus estimate of €2.27 billion. BioNTech expects revenue to be primarily concentrated in the last three to four months of the year.

The company maintained a robust financial position with €16.0 billion in cash and investments as of June 30, 2025. R&D expenses decreased 13% YoY to €509.1 million due to clinical trial reprioritization, reflecting the company’s focus on cost discipline while advancing its oncology pipeline.

BioNTech also received European Commission approval for its new variant-adapted COVID-19 vaccine, with deliveries expected to begin in August 2025. The company announced plans to acquire CureVac to strengthen its mRNA capabilities for cancer immunotherapies, further advancing its strategic transformation.

"While we continue to significantly invest into the execution of our strategy, our commitment to operational and financial discipline is starting to show tangible results," said Ramón Zapata, Chief Financial Officer at BioNTech.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.